(@suntoc SHL/SEC/ 14.02.2017 To, ‘The Manager, Bombay Stock Exchange Ltd. Dept. of Corporate Service P J Towers, Dalal Street, Mumbai-400001 Scrip Code;-537253 (BSE) and Nine Month FY 2017 Investor Release Dear Sir, With reference to the above cited subject, please find enclosed the Quarter -3 and Nine Month FY 2017 Investor Release Investor Release. This is your information and record please. Thanking you. Your Faithfully For SUNIL HEALTHCARE LIMITED nade ea, AGM Legal cum Company Secretary CC. Calcutta Stock Exchange Ltd. 7, Lyons Range Kolkata- 700 001 ‘Sunil Healthcare Limited Vijay Tower, 386/252 ~ 8, Shahpur Jat, Panchsheel Park Commercial New Dethi-130049 ‘T +91 11.49435555/00 Fi +91 11 43850087 e-mall info@sunihealtheare.com Web.’ wwwn.sunie (CIN Nos 24302011973°.c189662,@sunvoc Sunil eolthcre = 9MFY17 INVESTOR RELEASE 9MFY17: Revenue Growth at 25.38% YoY; 9MFY17: PAT Growth at 23.20 % YoY February 13", 2017, New Delhi: Sunil Healthcare Ltd, a leading manufacturer of Empty Hard Gelatin Capsules, has announced its Standalone Un-audited Financial Results for the Quarter & Nine Months ended 31* December 2016. ‘Key Financial Highlights: Rs In Millions ‘asrva7 | asrris | YoV% | oweva7 | omevie | Yor% Net Revenue 2173 | 25087 | 124% | 73557 | sera | 25.30% EBITDA asos | 4329 | arm | 13597 | 11756 | 15.66% EBITDA Margin 16.35% | 17.28% | (93)6ps_| 18.46% | 20.01% | (255)bes Profit Before Tax zaso | eo | 147mm | 7355 | 6197 | 18.69% PAT 1663 | 14a2 | 129% | 49.26 | 3997 | 23.20% PAT Margin sa0% | 592% | (ajops | 6.68% | 680% | (a2)bpe ‘Cash PAT zso_| 2452 | 13356 | ess | 6593 | 22.00% ‘ash PAT Margin 987% | 978% | sbps | 108% | 1139% | _(ao)bps £5 (Rs) 162 sas | anzex |. 480 390 | 2308% ‘9MEY17 - Performance Highlights: ‘Commenting on the results, Mr. D. Gnanasekaran (CEQ) said, “We are pleased to report strong operating numbers in the backdrop of extremely challenging market conditions which have adversely impacted our Realizations per unit. Despite facing headwinds on various facets, our Revenue in ‘9MFY27 has grown by 25.38% YoY while for Q3 the growth was 12.43% YoY. Our 9MFY17 PAT has {grown by 23.20% YoY while for Q3 growth was 12.19% on YoY.” A brief summary of our Capsule business performance is as under: Fs. In Millions aari7_|_asrris_|_YOY* | omevay | ammvae | Yov% | Net Revenue 20534 | 20788 | 120% | 62179 | sensi | s4aa% [eema 46.00 ass2_| a96% | 13828 | 11981 | 15.42% EBITDA Margin 22.40% | 21.08% | 132s | 22.24% | 21.99% | 2sbps Profit Before Tax | 24.82 zz | 169% | 75.86 a2 | sa34% PAT 16.58 asia | 9.23% 50.78 aia7_| 22.46% PAT Margin som | 730% | 779s | s17% | 7.61% | s6bps Cash PAT 2775 zas7_ | 157% | 93.23 e8.4¢ | 21.61% Cash PAT Margin aasix | 11.96% | assbps_| 13.39% | 12.56% | a3bps Our Capsules sales volume has grown by 31 % in the 9 month period for ths fiscal. This volume growth hhas been possible through continued focus on market diversifications across geographies coupled with@sunvoc sustained efforts to increase product share with existing customers. Our focus on product mix ‘optimization is helping us gaining market share in these tough environments. Volume growth coupled with a focussed approach on cost optimization has led to Operational Efficiencies being realized which have led to a healthy growth in operating margins on a YoY basis. Our ppefformance in the current Fiscal despite challenging market conditions has contributed to a growth ‘of 15.42% YoY in our EBIDTA for 9MFY17, and a growth of 4.96% YoY basis for O3FY17. In.Q3, we witnessed a steep increase in Power costs in Rajasthan and the same has been partly offset part by rationalising our power consumptions.. Insite of multiple challenges, our SMFY17 PAT from the Capsule business grew by 22.4636 YoY while for Q3F¥17 growth was 9.23% Yor. : ‘The past few months have been challenging for the Capsule industry both on the Domestic and Global fronts. Currency Volatility in the Emerging Economies have resulted in lower export Sales, leading to surplus capacities being channelized into the domestic market creating pricing pressures. Given this backdrop, our performance has been noteworthy. Our diverse product basket, decade old relationships with pharmaceutical majors and a focussed approach on execution have allowed us to ‘augment our position in our Industry. Our reach in multiple geographies in the Developed and Emerging markets have also provided a hedge in these challenging times. We expect this phase to continue for the next few quarters. We will continue to work towards ‘optimizing our performance in the given circumstances. Once the Industry reaches normalcy, we are confident of improving our performance further given our economies of scale and other operating leverages. We remain optimistic and focussed on being at the front end of this Industry which rem: our core focus area for growth. Inline with the above, we are pleased to inform that we have set up our subsidiary in Mexico with the aim of developing and establishing our presence in that market through our own front end. (On our performance in the Foods Division, we are pleased to report that our sustained efforts to develop a robust supply chain has enabled us to report a healthy growth in this vertical. We remain ‘optimistic on the growth prospects of this business. ‘About Sunil Ltd Sunil Healthcare Ltd, is the second largest manufacturer of Empty Hard Gelatin Capsules in India. A Gol recognized Star Export House, ~40% of revenues are from exports. With four decades of ‘experience, and a strong brand equity “Sunloc’, the company is a preferred vendor for large pharmaceutical companies. ‘The company was the pioneer of Double lock and Triple lock technology in India. With a strong focus ‘on R&D, the company is constantly innovating its product line to cater to the industry requirements. For more information, please visit the company website www.sunilhealthcare.com@sunvoc ‘Safe harbor statement Statementsin this document relating to future status, events or circumstances, including but not limited to statements about plons and objectives, the progress and results of research and development, potential project characteristic, project potential ond torget dotes fr project related issues ore forwordrlooking statements based on estimates ond the anticipated effects of future events on current and developing circumstances. Such statements are subject to rumerous risks ond uncertointes and ore not necessriy predictive of future results. Actuol results may difer ‘materially from those anticipated inthe forward-looking statements. The company assumes no obligation to update Jorwardlooking statements to reflect actual results changed assumptions or other factors For Fi ‘company: Investor Relations Advisors: Sunil Healthcare ta, ‘Strategic Growth Advisors Pvt td. cin cesosoyleysaeliseas CIN - U74140MH2010°TC204285 Mr. Pawan Rathi, os ‘Mr. Shogun Jain / Ms. Payal Dave Chiet Financial OF +991 7738377756 / +91 9819916314 cfo@sunithealtheare,camt shogunJjain@szaplnet / pavaldave@sgapLnet vow, sunilhealthcare.com www seaplnet